|

elacestrant, palbociclib, abemaciclib, ribociclib Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • Northwestern University1

Indications

  • Advanced Breast Cancerv1
  • HER2/Neu-Negative Breast Cancer1
  • Estrogen Receptor-positive Breast Cancer1
  • Metastatic Breast Cancer1
  • Breast Cancer1

Chicago, Illinois1 trial

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Northwestern University

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.